SCHEDULE: Alger Associates Boosts Forte Bio Stake to 13.3%

Alger Associates, Inc. has reported a 13.3% beneficial ownership stake in Forte Biosciences, Inc.'s common stock as of June 30, 2025.

Summary

• Alger Associates, Inc. reported beneficial ownership of 1,618,649 shares of Forte Biosciences, Inc. common stock.
• This ownership represents 13.3% of the total class of securities.
• The filing date for this Schedule 13G Amendment No. 6 is August 14, 2025, with the event triggering the filing occurring on June 30, 2025.
• Alger Associates, Inc. holds sole voting power over 1,608,040 shares and sole dispositive power over 1,618,649 shares.
• The securities are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC, a 100% owned subsidiary of Alger Group Holdings, LLC, which is a 100% owned subsidiary of Alger Associates, Inc.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Forte Biosciences, Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by a reputable asset manager, Alger Associates, Inc., in Forte Biosciences, Inc., which can be viewed positively as a vote of confidence from a large institutional investor. The certification that the shares are held in the ordinary course of business and not for control purposes suggests a stable, long-term investment.

Positives

• A significant institutional investor, Alger Associates, Inc., has taken a substantial 13.3% stake in Forte Biosciences, Inc., indicating confidence in the company.
• The acquisition of shares was certified as being in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, suggesting a stable, passive investment.

Negatives

• NA

Risks

• The filing itself does not detail specific risks related to Forte Biosciences, Inc.'s operations or financial health. It only states that the shares were not acquired for the purpose of influencing control, which mitigates a potential risk of activist investor intervention.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Forte Biosciences, Inc.'s future operations or financial performance. It solely reports a change in beneficial ownership by an institutional investor.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This Schedule 13G filing indicates a significant passive investment by a major asset manager, Alger Associates, Inc., in Forte Biosciences, Inc. Such filings are common for institutional investors crossing ownership thresholds and typically reflect a long-term investment strategy rather than an active attempt to influence company operations. This type of disclosure is standard in the financial industry for transparency regarding large shareholdings.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May view the significant institutional ownership as a positive signal of confidence in Forte Biosciences, potentially leading to increased investor interest and perceived stability.
• Company Management: The presence of a large, passive institutional investor like Alger Associates, Inc. provides a stable shareholder base without immediate pressure for strategic changes, allowing management to focus on long-term objectives.

Next Steps

• NA

Key Dates

Recommendation

This Schedule 13G filing indicates that Alger Associates, Inc. has acquired a significant 13.3% passive stake in Forte Biosciences, Inc. While this demonstrates institutional confidence and provides a stable shareholder base, the filing itself does not contain operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily serves as a disclosure of ownership. For existing investors, it reinforces a 'hold' position given the institutional backing. For potential investors, it suggests further due diligence on Forte Biosciences' fundamentals is warranted, as the institutional stake is a positive indicator.

Keywords

Forte Biosciences, Alger Associates, Common Stock, Institutional Ownership, SEC Filing, Schedule 13G, Investment Management, Biotechnology